Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Replimune Group, Inc.REPL · Entity 4707 | Chief Medical Officer | April 01, 2021 | April 05, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Replimune Group, Inc.
Report date April 01, 2021 · Filed April 05, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 21,500 |
Reported balance
After 2021-04-01 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2021-04-01 · Grant · Acquired 20,500 · Balance 21,500 F1: Represents shares of the Issuer's common stock issuable upon settlement of restricted stock units ("RSUs") granted to the Reporting Person. Each RSU represents a contingent right to receive one share of the Issuer's common stock. 25% of the RSUs will vest on May 15, 2022 and the remainder will vest in three approximately equal annual installments thereafter until May 15, 2025, subject to the Reporting Person's continuous service to the Issuer. F2: 1,000 shares of the Issuer's common stock are held by the Reporting Person's husband. The Reporting Person may be deemed to be the beneficial owner of such shares. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $31.58 · Expires 2031-04-01 | Direct | 30,750 |
Reported balance
After 2021-04-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-04-01 · Grant · Acquired 30,750 · Balance 30,750 F3: 25% of the shares underlying this stock option vest on April 1, 2022, and the remainder of the shares underlying this stock option vest in 36 approximately equal monthly installments thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares of the Issuer's common stock issuable upon settlement of restricted stock units ("RSUs") granted to the Reporting Person. Each RSU represents a contingent right to receive one share of the Issuer's common stock. 25% of the RSUs will vest on May 15, 2022 and the remainder will vest in three approximately equal annual installments thereafter until May 15, 2025, subject to the Reporting Person's continuous service to the Issuer.
F2: 1,000 shares of the Issuer's common stock are held by the Reporting Person's husband. The Reporting Person may be deemed to be the beneficial owner of such shares.
F3: 25% of the shares underlying this stock option vest on April 1, 2022, and the remainder of the shares underlying this stock option vest in 36 approximately equal monthly installments thereafter.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 01, 2021 Filed Apr 5, 2021 20:19 UTC | Replimune Group, Inc. REPL · Entity 4707 | GrantEmployee Stock Option (right to buy) · Derivative | 30,750 | $0.00 Strike: $31.58 | $0.00 |
DisclosureSEC source: 0001104659-21-046732 · tm2112099-13_4seq1.xml · derivative · entry 2 Pirzkall Andrea · CIK 0001818578 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,750 Underlying: Common Stock · 30,750 shares Expires 2031-04-01 F3 · derivative.exercise_date: 25% of the shares underlying this stock option vest on April 1, 2022, and the remainder of the shares underlying this stock option vest in 36 approximately equal monthly installments thereafter. Read SEC document |
| April 01, 2021 Filed Apr 5, 2021 20:19 UTC | Replimune Group, Inc. REPL · Entity 4707 | GrantCommon Stock | 20,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-046732 · tm2112099-13_4seq1.xml · nonDerivative · entry 1 Pirzkall Andrea · CIK 0001818578 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,500 F1 · shares: Represents shares of the Issuer's common stock issuable upon settlement of restricted stock units ("RSUs") granted to the Reporting Person. Each RSU represents a contingent right to receive one share of the Issuer's common stock. 25% of the RSUs will vest on May 15, 2022 and the remainder will vest in three approximately equal annual installments thereafter until May 15, 2025, subject to the Reporting Person's continuous service to the Issuer. F2 · balance_after: 1,000 shares of the Issuer's common stock are held by the Reporting Person's husband. The Reporting Person may be deemed to be the beneficial owner of such shares. Read SEC document |
| July 20, 2020 Filed Jul 22, 2020 08:14 UTC | Replimune Group, Inc. REPL · Entity 4707 | GrantEmployee Stock Option (right to buy) · Derivative | 300,000 | $0.00 Strike: $22.45 | $0.00 |
DisclosureSEC source: 0001104659-20-085403 · a4.xml · derivative · entry 1 Pirzkall Andrea · CIK 0001818578 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 300,000 shares Expires 2030-07-20 F1 · derivative.exercise_date: 25% of the shares underlying this stock option vest on July 20, 2021 and the remainder of the shares underlying this stock option vest in 36 approximately equal monthly installments thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.